Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AVA-001,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia; Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity or Adverse Side Effects.
Product Name : AVA-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 13, 2020
Lead Product(s) : AVA-001,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AVA-001,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) have achieved complete remission (CR rate of 90%) within one month after the initiation of AVA-001 CAR T-cell therapy treatment.
Product Name : AVA-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 29, 2020
Lead Product(s) : AVA-001,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : S-Layer COVID Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : University Of Natural Resources
Deal Size : Undisclosed
Deal Type : Partnership
Avalon GloboCare to Develop Intranasal and Oral Covid-19 Vaccine
Details : Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B. Sleytr on a novel S-layer SARS-CoV-2 (COVID-19) vaccine.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 25, 2020
Lead Product(s) : S-Layer COVID Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : University Of Natural Resources
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : AVA-Trap
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Avalon’s AVA-Trap™ therapeutic program is currently entering animal model testing followed by expedited clinical studies with the goal of providing an effective therapeutic option to combat COVID-19.
Product Name : AVA-Trap
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
April 20, 2020
Lead Product(s) : AVA-Trap
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Avalon is expanding its AVA-001 clinical trial to recruit patients with relapsed/refractory Non-Hodgkin lymphoma (R/R-NHL).
Product Name : AVA-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 10, 2020